Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $8.3 million.

  • Janux Therapeutics' Cash from Investing Activities fell 34.46% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.6 million, marking a year-over-year decrease of 5.62%. This contributed to the annual value of -$258.0 million for FY2024, which is 526.36% down from last year.
  • Latest data reveals that Janux Therapeutics reported Cash from Investing Activities of $8.3 million as of Q3 2025, which was up 431.75% from $1.6 million recorded in Q2 2025.
  • Janux Therapeutics' Cash from Investing Activities' 5-year high stood at $33.9 million during Q4 2024, with a 5-year trough of -$340.4 million in Q1 2025.
  • For the 3-year period, Janux Therapeutics' Cash from Investing Activities averaged around -$57.2 million, with its median value being $1.6 million (2025).
  • In the last 5 years, Janux Therapeutics' Cash from Investing Activities surged by 20,405.88% in 2022 and then tumbled by 1,201.33% in 2024.
  • Janux Therapeutics' Cash from Investing Activities (Quarterly) stood at $7.3 million in 2021, then slumped by 121.89% to -$1.6 million in 2022, then surged by 793.45% to $11.1 million in 2023, then spiked by 205.01% to $33.9 million in 2024, then tumbled by 34.46% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $1.6 million for Q2 2025, and -$340.4 million during Q1 2025.